Association between EML4-ALK fusion gene and thymidylate synthase mRNA expression in non-small cell lung cancer tissues

Experimental and Therapeutic Medicine

Volumn 9, Issue 6, 2015, Pages 2151-2154

  Xu, Chun Wei ^a   Wang, Gang ^b   Wang, Wu Long ^b,c   Gao, Wen Bin ^b   Han, Chuan Jun ^b   Gao, Jing Shan ^d   Zhang, Li Ying ^a   Li, Yang ^a   Wang, Lin ^e   Zhang, Yu Ping ^f   Tian, Yu Wang ^a   Qi, Dong Dong ^b  

^a Beijing Military Hospital PLA   (China)

^b DALIAN UNIVERSITY   (China)

^c BAOTOU MEDICAL COLLEGE   (China)

^d DALIAN MEDICAL UNIVERSITY   (China)

^e Shanxi Dayi Hospital   (China)

^f WEIFANG PEOPLE'S HOSPITAL   (China)

Author keywords

EML4 ALK; Individual treatment; Molecular detection; Non small cell lung cancer; Thymidylate synthase

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ECHINODERM MICROTUBULE ASSOCIATED PROTEIN LIKE 4; MESSENGER RNA; MICROTUBULE ASSOCIATED PROTEIN; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; FUSION GENE; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON SMALL CELL LUNG CANCER; POLYMERASE CHAIN REACTION;

EID: 84928253331     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2015.2372     Document Type: Article

References (24)

1. Jemal A, Bray F, Canter MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Sher T, Dy GK and Adjei AA: Small cell lung cancer. Mayo Clin Proc 83: 355-367, 2008.
3. Horn L and Pao W: EML4-ALK: Honing in on a new target in non-small-cell lung cancer. J Clin Oncol 27: 4232-4235, 2009.
4. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, et al: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448: 561-566, 2007.
5. Inamura K, Takeuchi K, Togashi Y, Nomura K, Ninomiya H, Okui M, Satoh Y, Okumura S, Nakagawa K, Soda M, et al: EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol 3: 13-17, 2008.
6. Perner S, Wagner PL, Demichelis F, Mehra R, Lafargue CJ, Moss BJ, Arbogast S, Soltermann A, Weder W, Giordano TJ, et al: EML4-ALK fusion lung cancer: A rare acquired event. Neoplasia 10: 298-302, 2008.
7. Wong DW, Leung EL, So KK, Tam IY, Sihoe AD, Cheng LC, Ho KK, Au JS, Chung LP and Pik Wong M; University of Hong Kong Lung Cancer Study Group: The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 115: 1723-1733, 2009.
8. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S, McDermott U, et al: Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27: 4247-4253, 2009.
9. Martelli MP, Sozzi G, Hernandez L, Pettirossi V, Navarro A, Conte D, Gasparini P, Perrone F, Modena P, Pastorino U, et al: EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol 174: 661-670, 2009.
10. Sasaki T, Rodig SJ, Chirieac LR and Jänne PA: The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer 46: 1773-1780, 2010.
11. Diasio RB and Johnson MR: The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil. Pharmacology 61: 199-203, 2000.
12. Fukushima M, Morita M, Ikeda K and Nagayama S: Population study of expression of thymidylate synthase and dihydropyrimidine dehydrogenase in patients with solid tumors. Int J Mol Med 12: 839-844, 2003.
13. Chu E, Copur SM, Ju J, Chen TM, Khleif S, Voeller DM, Mizunuma N, Patel M, Maley GF, Maley F and Allegra CJ: Thymidylate synthase protein and p53 mRNA form an in vivo ribonucleoprotein complex. Mol Cell Biol 19: 1582-1594, 1999.
14. Kawakami K, Graziano F, Watanabe G, Ruzzo A, Santini D, Catalano V, Bisonni R, Arduini F, Bearzi I, Cascinu S, et al: Prognostic role of thymidylate synthase polymorphisms in gastric cancer patients treated with surgery and adjuvant chemotherapy. Clin Cancer Res 11: 3778-3783, 2005.
15. Righi L, Papotti MG, Ceppi P, Billè A, Bacillo E, Molinaro L, Ruffini E, Scagliotti GV and Selvaggi G: Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. J Clin Oncol 28: 1534-1539, 2010.
16. Gomez HL, Santillana SL, Vallejos CS, Velarde R, Sanchez J, Wang X, Bauer NL, Hockett RD, Chen VJ, Niyikiza C and Hanauske AR: A phase II trial of pemetrexed in advanced breast cancer: Clinical response and association with molecular target expression. Clin Cancer Res 12: 832-838, 2006.
17. Kwak EL, Bang YJ, Camidge DR, et al: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363: 1693-1703, 2010.
18. Kim DW, Ahn MJ, Shi YK, et al: Updated results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol 30 (Suppl): abstr 7533, 2012.
19. Shaw AT, Kim DW, Nakagawa K, et al: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368: 2385-2394, 2013.
20. Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T, Yatabe Y, Takeuchi K, Hamada T, Haruta H, et al; ALK Lung Cancer Study Group: EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 363: 1734-1739, 2010.
21. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, Nardone J, Lee K, Reeves C, Li Y, et al: Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131: 1190-1203, 2007.
22. Zhang X, Zhang S, Yang X, Yang J, Zhou Q, Yin L, An S, Lin J, Chen S, Xie Z, et al: Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol Cancer 9: 188, 2010.
23. Sun Y, Ren Y, Fang Z, Li C, Fang R, Gao B, Han X, Tian W, Pao W, Chen H and Ji H: Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. J Clin Oncol 28: 4616-4620, 2010.
24. Gandara DR, Huang E and Desai S: Thymidylate synthase (TS) gene expression in patients with ALK positive(+) non-small cell lung cancer (NSCLC): Implications for therapy. J Clin Oncol 30 (Suppl): a7582, 2012.